Enoxaparin Dosing in Renal Impairment

Introduction to Enoxaparin Dosing

• The American College of Cardiology and other guideline societies recommend enoxaparin dosing adjustments based on both the indication and the degree of renal impairment, with specific dose reductions required for patients with severe renal dysfunction (CrCl <30 mL/min) 1, 2

Standard Dosing in Normal Renal Function

• For patients with normal renal function, the standard dose for DVT prophylaxis is 40 mg subcutaneously once daily 1
• For patients with normal renal function, the standard dose for DVT treatment is 1 mg/kg subcutaneously every 12 hours OR 1.5 mg/kg once daily 3

Critical Dose Adjustments in Severe Renal Impairment (CrCl <30 mL/min)

• For DVT prophylaxis in patients with severe renal impairment, the dose should be reduced to 30 mg subcutaneously once daily, representing a 25% dose reduction from standard prophylactic dosing 1, 2, 4
• For DVT treatment in patients with severe renal impairment, the dose should be reduced to 1 mg/kg subcutaneously once daily, representing a 50% total daily dose reduction from standard therapeutic dosing 1, 2, 4

Pharmacokinetic Rationale for Dose Reduction

• Enoxaparin clearance is reduced by 44% in patients with CrCl <30 mL/min, leading to drug accumulation and increased bleeding risk without dose adjustment 1, 4
• Unadjusted therapeutic dosing increases major bleeding risk nearly 4-fold (8.3% vs 2.4%) 4

Moderate Renal Impairment (CrCl 30-50 mL/min)

• Enoxaparin clearance is reduced by 31% in patients with moderate renal impairment, and dose reduction should be considered 1

Monitoring Recommendations

• Anti-Xa monitoring is recommended in patients with severe renal impairment, with target therapeutic range of 0.5-1.5 IU/mL for once-daily treatment dosing and 0.29-0.34 IU/mL for prophylactic dosing 1, 2, 4

Alternative Anticoagulation Strategy

• Unfractionated heparin (UFH) is a preferred alternative for therapeutic anticoagulation in patients with severe renal impairment, with dosing of 60 U/kg IV bolus followed by 12 U/kg/hour infusion 3, 4
• Fondaparinux is contraindicated in patients with CrCl <20-30 mL/min 3, 4

Special Populations Requiring Extra Caution

• Elderly patients (≥70 years) with renal impairment require extreme caution due to high-risk factors for bleeding, and tinzaparin should be avoided entirely in this population 1, 2, 4
• Underweight patients (<50 kg) with renal impairment require close monitoring of anti-Xa levels and reduced dosing 4

Critical Safety Considerations

• Failure to reduce doses in severe renal impairment leads to drug bioaccumulation and substantially increased bleeding complications 2
• Among all low-molecular-weight heparins, only enoxaparin has specific FDA-approved dosing recommendations for patients with CrCl <30 mL/min, making it the preferred LMWH when anticoagulation is required in severe renal impairment 1, 2